Patent Publication Number: US-2009220522-A1

Title: Detoxified Endotoxin Vaccine and Adjuvant and Uses thereof

Description:
CROSS REFERENCE TO RELATED APPLICATION 
     This U.S. national stage application filed under 35 U.S.C. §363 claims benefit of priority under 35 U.S.C. §365 of international application PCT/US2006/41477, filed Oct. 24, 2006, now abandoned, which claims benefit of priority under 35 U.S.C. § 119(e) of provisional U.S. Ser. No. 60/729,570, filed Oct. 24, 2005, now abandoned. 
    
    
     FEDERAL FUNDING LEGEND 
     This invention was produced using funds obtained through a National Institutes of Health grant (ROI-AI-42181-04AI) and Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases Research grants (U54 AI057168 &amp; U54 AI057159). Consequently, the Federal government has certain rights in this invention. 
    
    
     BACKGROUND OF THE INVENTION 
     1. Field of the Invention 
     The present invention relates generally to the field of immunology and vaccine development. More specifically, the present invention provides a immunogenic composition, comprising a lipopolysaccharide vaccine and a Toll-like receptor 9 (TLR9) agonist and its use in the prevention and treatment of sepsis and infection with biodefense agents. 
     2. Description of the Related Art 
     Gram-negative bacteria are causative agents of many life-threatening ailments which include pneumonia, plague, tularemia, meliodosis and sepsis. These bacteria can also be used as biowarfare agents. Gram-negative bacterial sepsis is a serious complication in patients residing in intensive care units (ICUs), undergoing abdominal surgery or incurring trauma or burns and in patients that develop prolonged neutropenia. Although antibiotic therapy plays an important role in limiting the incidence of this complication, there has been little change in the mortality of this condition once it develops as seen in the last few decades. Consequently, there has been considerable effort to devise new therapies to complement the advances in supportive care and anti-microbial therapy. An example of such therapy that is being explored is the use of vaccines. 
     Active or passive immunization with Gram negative bacterial endotoxin (or lipopolysaccharide, LPS) protects against lethal infection upon subsequent exposure to the same serotype of the organism from which the lipopolysaccharide was derived (known as “homologous protection”). However, such a vaccine does not protect against Gram-negative bacteria from other serotypes of that same species of bacteria or from different Gram-negative bacterial species (i.e. “heterologous” bacteria). This is because the antibody thus elicited is directed against the outermost sugars of the lipopolysaccharide molecule, each of which is specific for that one serotype. 
     In contrast, the core portion of the lipopolysaccharide (also called “core glycolipid”) is widely conserved among many different Gram-negative bacteria such that antibodies directed against this core glycolipid provide heterologous protection i.e. protect against subsequent challenge with a wide spectrum of clinically relevant Gram-negative bacterial pathogens (Cross et al., 2003; Bhattacharjee et al., 1996). Antibodies against an even more widely conserved region of the lipopolysaccharide molecule, the lipid A, have not been shown to be protective in either experimental or clinical studies of sepsis. 
     The ability of one such vaccine comprising lipopolysaccharide of an Rc chemotype mutant of  E. coli  0111:B4 ( E. coli  J5) to provide protection against an array of Gram negative bacteria was examined in a previous study. The preparation of such a vaccine involved detoxification of the lipopolysaccharide first by alkaline treatment to cleave ester-linked fatty acids of the lipid A component of lipopolysaccharide followed by non-covalent complexing with the outer membrane protein (OMP) of  Neisseria meningitidis  Group B. This dLPS-J5/OMP vaccine protected against lethal gram-negative bacterial sepsis when administered either actively (as a vaccine preventive strategy) or passively (as immune plasma) in a neutropenic rat model of  Pseudomonas  sepsis (Bhattacharjee et al., 1996; Bhattacharjee et al., 1994; Cross et al., 2001). This vaccine was also used in the phase I clinical study in human subjects where these subjects were actively immunized with the vaccine (Cross et al., 2003). 
     Although the dLPS-J5/OMP vaccine demonstrated greater than 20 fold IgG antibody response to the core glycolipid structure of lipopolysaccharide in rabbits, mice and rats, human volunteers developed only a 2-3 fold increase above baseline antibody titers (Cross et al., 2003). The antibody response was polyclonal with generation of both IgM and IgG antibodies that persisted for at least 12 months (Cross et al., 2001). 
     Furthermore, previous passive protection studies had indicated that protection against lethal sepsis was dependent on the concentration of the antibody passively administered. It is also known that an immunogenicity to an antigen can be enhanced by administering the antigen in combination with an adjuvant. Examples of commonly used adjuvants in vaccine preparations include aluminium potassium sulfate, Freund&#39;s incomplete adjuvant, Freund&#39;s complete adjuvant, alum, synthetic polyribonucleotides and bacterial lipopolysaccharides. 
     Bacterial DNA and synthetic oligodeoxynucleotides (ODN) that contain immunostimulatory unmethylated CpG motifs (CpG ODN) are potent TLR9 agonists (Bauer et al., 2001; Hemmi et al., 2000) and have been shown to be potent B cell activators and effective immunoadjuvants when combined with a wide variety of types of antigens, including peptide-based vaccines (McCluskie et al., 2001). The CpG motifs also promote a Th1 type immune response which may further promote a combined innate and adaptive immune response essential to resist microbial invasion and promote antibacterial defense mechanisms (Weighardt et al., 2000). Additionally, these synthetic oligodeoxynucleotides have potentially benefited patients with asthma, enhance innate host defenses against neoplasia (Wild and Sur, 2001; Rothenfusser et al., 2003), and improve human vaccine responses (Halperin et al., 2003). Despite the efficacy of the CpG oligodeoxynucleotides to function as an immunoadjuvant, to date CpG oligodeoxynucleotides have been used as vaccine adjuvants with primarily protein, protein/polysaccharide conjugates and with DNA vaccines (McCluskie et al., 2001; Wild and Sur, 2001; Rothenfusser et al., 2003; Halperin et al., 2003). 
     Thus, prior art is deficient in a vaccine that elicits a high antibody titer to offer protection against a wide array of Gram negative bacteria as well as monoclonal antibodies to treat infection by such bacteria. The current invention fulfils this long standing need in the art. 
     SUMMARY OF THE INVENTION 
     In one embodiment of the present invention, there is provided an immunogenic composition comprising a lipopolysaccharide vaccine and a Toll-like receptor 9 (TLR9) agonist. 
     In a related embodiment of the present invention, there is provided a method of preventing an infection caused by Gram-negative bacteria in an individual. This method comprises administering an immunologically effective amount of the immunogenic composition described supra to the individual. 
     In another embodiment of the present invention, there is provided an immunogenic composition comprising an anti-endotoxin antibody directed against the core portion of a Gram-negative bacterial lipopolysaccharide. 
     In a related embodiment of the present invention, there is provided a method of treating an infection caused by Gram-negative bacteria in an individual. This method comprises administering effective amount of the composition comprising the antibody described supra. Thus, this method of the present invention treats the infection caused by Gram-negative bacteria. 
     In yet another embodiment of the present invention, there is provided a method of preventing an infection caused by Gram-negative bacteria in an individual. This method comprises administering to the individual an immunogenic composition comprising a detoxified J5 core lipopolysaccharide of  E. coli  non-covalently complexed with group B meningococcal outermembrane protein at a concentration of about 5 μg to about 50 μg and a CpG 7909 oligodeoxynucleotide at a concentration of about 250 μg to about 500 μg. 
     In still yet another embodiment of the present invention, there is provided an anti-endotoxin monoclonal antibody. Such an antibody is raised against a Gram-negative bacterial lipopolysaccharide vaccine and a Toll-like receptor 9 (TLR9) agonist. 
     In a further related embodiment of the present invention, there is provided a method of treating an infection caused by a Gram-negative bacteria in an individual. This method comprises administering immunologically effective amounts of the monoclonal antibody described supra, thereby treating the infection caused by the Gram-negative bacteria in the individual. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       The appended drawings have been included herein so that the above-recited features, advantages and objects of the invention will become clear and can be understood in detail. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and should not be considered to limit the scope of the invention. 
         FIG. 1  shows the Kaplan-Meier survival plot of actively immunized BALB/c mice with the dLPS-J5/OMP vaccine; dLPS-J5/OMP vaccine+CpG oligodeoxynucleotides; CpG oligodeoxynucleotides+saline control group (day −6); and CpG oligodeoxynucleotides+saline control group (day −30). Both vaccine groups had a significantly greater survival rate than the CpG oligonucleotides+saline (day −30) control group (P&lt;0.01 for both vaccine groups vs. control). 
         FIG. 2  shows a decrease in geometric mean antibody concentrations as a ratio of specific IgG antibody in immunized mice before and 48 hours after CLP. Open bars—anti-core glycolipid lipopolysaccharide antibody; hatched bars—total IgG immunoglobulin; solid bars—anti-OMP (meningococcal outer membrane protein) antibody ratios. 
         FIGS. 3A-B  show that the antibody induced by the vaccine was able to bind to various select agents and to whole bacteria.  FIG. 3A  shows the binding of the antibody to whole bacterial cells.  FIG. 3B  shows the binding of the antibody to the biodefense LPS. 
         FIGS. 4A-E  shows the data from ex vivo functional assay that was performed using whole blood.  FIG. 4A  shows the data of the ex vivo assay on whole blood.  FIG. 4B  shows the serum IgG levels.  FIG. 4C  shows the BAL IgG levels  FIG. 4D  shows the serum IgA levels.  FIG. 4E  shows the BAL IgA levels. 
         FIG. 5  shows the effect of the vaccine after intratracheal challenge. 
         FIGS. 6A-6D  show effect of J5dLPS-OMP (J5) in female outbred white (Cr1:CD-1(ICR)BR) mice. Mice were immunized with 1 μg of J5dLPS-OMP (J5) at weeks 0, 2 and 4±25 μg of CpG at week 0. BALF and serum was collected at week 6. ELISA anti-CGL antibody responses are illustrated in the bar graphs as arithmetic mean and 95% CI for serum IgG ( FIG. 6A ), BALF IgG ( FIG. 6B ), serum IgA ( FIG. 6C ) and BAL IgA ( FIG. 6D ) responses. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 by Mann-Whitney test. ND=non-detectable, IN=intranasal, IP=intraperitoneal. 
         FIG. 7  shows Kaplan Meier survival curves from the sum of two intratracheal (IT) challenge experiments. Mice were immunized with 1 μg of J5dLPS-OMP and 25 μg of CpG on weeks 0, 2 and 4 and challenged IT with  Klebsiella pneumoniae  E1757 at 5.8-6.3×10 4  CFU per mouse at week 6. 12 mice per group received i.n. J5dLPS-OMP with CpG (IN) or i.n. PBS (control). *p=0.0148 by Log rank test. 
         FIG. 8  shows Kaplan Meier survival curves from the sum of three IT with  Klebsiella pneumoniae  E1757 at 7.6-9.5×10 4  CFU per mouse at week 6. 21 mice received i.n. J5dLPS-OMP with CpG (IN), 20 mice received i.p. J5dLPS-OMP with CpG (IP) and 14 mice received i.n. PBS (control). *p=0.047 by Log rank test. 
         FIGS. 9A-9C  show bacterial counts that were assessed after freshly harvested primary macrophages were mixed with pre-opsonized bacteria using “high titer” immune serum, “high titer” immune BALF or “low titer” control BALF; each sample was derived from a mouse that received active immunization i.p. or i.n. or received i.n. CpG alone, respectively. Sterile PBS was used as mock pre-opsonization, designated as untreated bacteria. At 24 hours, peritoneal macrophages (PM, 106) demonstrated enhanced killing of  Klebsiella pneumoniae  O1:K2 (MOI 1:10, 10 5  CFU) ( FIG. 9A ) and  Pseudomonas aeruginosa  PAO1 (MOI 1:1, 10 6  CFU) ( FIG. 9B ) and alveolar macrophages (AM), 10 6 ) demonstrated a trend toward enhanced killing on  Pseudomonas aeruginosa  PAO1 (MOI 1:1, 10 6  CFU) ( FIG. 9C ). Data are expressed as means from experiments with comparisons for significance calculated against the control BALF responses. NS=not significant, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005 by two-tailed Student&#39;s t test. 
         FIG. 10  shows the bacterial counts at 5 hours that were assessed using freshly harvested primary PM (10 6 ) and PA01 (MOI 1:1, 10 6  CFU) that had been pre-opsonized with the same immune serum, immune BALF, or control BALF as discussed supra. The immune serum was diluted 1000 fold in order to approximate the anti-CGL IgG in the immune BALF. L-NIL was added to PM that were infected with PAO1 pre-opsonized with immune serum to inhibit nitric oxide-mediated macrophage killing. Data are expressed as means from two independent experiments conducted in duplicate and comparisons that were calculated against the control BAL response. NS=not significant, *p&lt;0.05, ***p&lt;0.005 by two-tailed Student&#39;s t test. 
         FIG. 11  shows the Kaplan-Meier survival curve for mice in a respiratory tularemia mouse model. 
         FIG. 12  shows that intratracheal (i.t) challenge with LVS (live attenuated FT vaccine) 4 weeks after the last immunization of BALB/c mice with vaccine+CpG conferred protection. Data represents two separate experiments. 
         FIGS. 13A-13E  show that protection against lethal LVS i.t challenge correlated with reduced levels of bacteria in blood, lung and liver at 96 hours.  FIG. 13A  compares bacteremia in control, mice immunized with J5 and those immunized with J5+CpG.  FIGS. 13B and 13C  show bacterial count in liver and lung, respectively.  FIG. 13D  shows that immunized mice had fewer PMNs recruited to the lungs.  FIG. 13E  shows bacterial counts in the lung during the early time points. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     I. Definitions 
     The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Some embodiments of the invention may consist of or consist essentially of one or more elements, method steps, and/or methods of the invention. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. 
     The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” 
     As used herein, the term “immunologically effective amount” refers to an amount that results in an improvement or remediation of the symptoms of the disease or condition due to induction of an immune response. Those of skill in the art understand that the effective amount may improve the patient&#39;s or subject&#39;s condition, but may not be a complete cure of the disease and/or condition. 
     As used herein, “active immunization” is defined as the administration of a vaccine to stimulate the host immune system to develop immunity against a specific pathogen or toxin. 
     As used herein, “passive immunization” is defined as the administration of antibodies to a host to provide immunity against a specific pathogen or toxin. 
     As used herein, “CpG oligonucleotides” are defined by the presence of an unmethylated CG dinucleotide in a CpG motif. 
     As used herein, “adjuvant” is defined as a substance which when included in a vaccine formulation non-specifically enhances the immune response to an antigen. 
     II. Present Invention 
     The present invention is directed to an immunogenic composition, comprising a lipopolysaccharide vaccine and a Toll-like receptor 9 (TLR9) agonist. Generally, the lipopolysaccharide vaccine may comprise a detoxified core lipopolysaccharide of a Gram-negative bacteria non-covalently complexed with group B meningococcal outer membrane protein (OMP). Representative examples of the core lipopolysaccharide in such a vaccine is not limited to but may include a J5 core lipopolysaccharide or any R a -R e  chemotype and a Gram-negative bacteria whose core lipopolysaccharide that can be used in the vaccines is not limited to but may include  Klebsiella, Pseudomonas, Burkholderia, Francisella, Yersinia, Enterobacter, E. coli, Serratia, Actinobacter, Salmonella  or  Shigella . Furthermore, the TLR9 agonist may be a synthetic oligodeoxynucleotide comprising one or more immunostimulatory unmethylated CpG motifs. Representative examples of such oligodeoxynucleotides that can be used as an immunoadjuvant in this immunogenic composition is not limited to but may include a CpG 7909 oligodeoxynucleotide, or any other immunostimulatory CpG oligodeoxynucleotide. 
     The present invention is also directed to a method of preventing an infection caused by Gram-negative bacteria in an individual, comprising: administering an immunologically effective amount of the immunogenic composition described supra. Generally, such a composition may enhance an antibody response, reduce the levels of inflammatory cytokines and the levels of endotoxins and decrease the bacterial load in the individual to prevent the infection caused by the Gram-negative bacteria in the individual. Examples of Gram-negative bacteria causing the infection is not limited to but may include  Klebsiella, Pseudomonas, Burkholderia, Francisella, Yersinia, Enterobacter, E. coli, Serratia, Actinobacter, Salmonella  or  Shigella . Generally, an individual benefiting from such a method may be one who is healthy, has incurred trauma, will or has undergone surgical procedure, is at high risk of developing occupation-related or heat related injuries or is at a risk of developing graft versus host disease subsequent to bone marrow or stem cell transplantation. Furthermore, the concentration of the vaccine in the immunogenic composition may be about 5 μg to about 50 μg and the concentration of the TLR9 agonist in the immunogenic composition may be about 250 μg to about 500 μg. Additionally, the immunogenic composition may be administered subcutaneously, intramuscularly, intranasally or mucosally. 
     The present invention is also directed to an immunogenic composition comprising an anti-endotoxin antibody directed against the core portion of a Gram-negative bacterial lipopolysaccharide. Such an antibody may be generated by a person having ordinary skill in this art using a lipopolysaccharide vaccine and a Toll-like receptor 9 (TLR9) agonist. All other aspects regarding the composition of the lipopolysaccharide vaccine, the types of core lipopolysaccharides, the Gram-negative bacteria that the lipopolysaccharides are derived from, the composition of the TLR9 agonist and the examples of such agonists are the same as discussed supra. 
     The present invention is further directed to a method of treating an infection caused by a Gram-negative bacteria in an individual, comprising: administering immunologically effective amounts of the immunogenic composition comprising the antibody described supra, thereby treating the infection caused by the Gram-negative bacteria in the individual. Additionally, this method may further comprise administering pharmacologically effective amounts of an antibiotic toxic to the Gram-negative bacteria. Such an antibiotic may be administered concurrent with, subsequent to or sequential to the administration of the antibody. The examples of Gram-negative bacteria causing the infection is the same as described supra. Additionally, the examples of individuals that will benefit from this method is not limited to but may include an individual who has incurred trauma, will undergo or has undergone a surgical procedure, is at high risk of developing occupation-related or heat-related injures or is at risk of developing graft versus host disease subsequent to bone marrow or stem cell transplantation. Furthermore, the antibody may be administered at a dose from about 100 mg/kg to about 1500 mg/kg. Examples of routes of administration of such preformed antibodies are not limited to but may include subcutaneous, intramuscular, intravenous or mucosal route. 
     The present invention is also directed to a method of preventing an infection caused by a Gram-negative bacteria in an individual, comprising: administering to the individual an immunogenic composition comprising a detoxified J5 core lipopolysaccharide of  E. coli  non-covalently complexed with group B meningococcal outer membrane protein at a concentration of about 5 μg to about 50 μg and a CpG 7909 oligodeoxynucleotide at a concentration of about 250 μg to about 500 μg. Generally, the composition may enhance antibody response, reduce the levels of inflammatory cytokines and the levels of endotoxins and decrease bacterial load in the individual to prevent the infection caused by the Gram-negative bacteria in the individual. All other aspects regarding examples of Gram-negative bacteria causing the infection, individuals that will benefit from this method and routes of administering the composition discussed supra. 
     The present invention is further directed to an anti-endotoxin monoclonal antibody, where the antibody is raised against a Gram-negative bacterial lipopolysaccharide vaccine and a Toll-like receptor 9 (TLR9) agonist. Generally, the antibody may bind the core portion of the Gram-negative bacterial lipopolysaccharide. Moreover, the lipopolysaccharide vaccine may comprise a detoxified core lipopolysaccharide of a Gram-negative bacteria non-covalently complexed with group B meningococcal outer membrane protein. Examples of the detoxified core lipopolysaccharide is not limited to but may include a J5 core lipopolysaccharide or any R a -R e  chemotype and that of the Gram-negative bacteria is not limited to but may include  Klebsiella, Pseudomonas, Burkholderia, Francisella, Yersinia, Enterobacter, E. coli, Serratia, Actinobacter, Salmonella  or  Shigella . Furthermore, the TLR9 agonist may be a synthetic oligodeoxynucleotide comprising one or more immunostimulatory CpG motifs. Additionally, examples of the oligodeoxynucleotide is not limited to but may include a CpG 7909 oligodeoxynucleotide or any immunostimulatory CpG oligonucleotide. 
     The present invention is still further directed to a method of treating an infection caused by a Gram-negative bacteria in an individual, comprising: administering immunologically effective amounts of the monoclonal antibody described supra, thereby treating the infection caused by the Gram-negative bacteria in the individual. This method may further comprise administering a pharmacologically effective amount of an antibiotic toxic to the Gram-negative bacteria. Generally, the antibiotic may be administered concurrent with, subsequent to or sequential to the administration of the antibody. Examples of the Gram-negative bacteria causing the infection is not limited to but may include  Klebsiella, Pseudomonas, Burkholderia, Francisella, Yersinia, Enterobacter, E. coli, Serratia, Actinobacter, Salmonella  or  Shigella . Examples of the kind of individual who will benefit from such a method is not limited to but may include one who has incurred trauma, will undergo or has undergone surgical procedure, is at high risk of developing occupation-related or heat-related injures or is at risk of developing graft versus host disease subsequent to bone marrow or stem cell transplantation. Generally, the antibody may be administered to the individual at a dose from about 100 mg/kg to about 1500 mg/kg and the antibody may be administered subcutaneously, intramuscularly, intravenously or mucosally. 
     The present invention discloses a novel vaccine adjuvant composition comprising detoxified Gram negative J5 core lipopolysaccharide/group B meningococcal outer membrane protein complex (dLPS-J5/OMP) as the vaccine and a Toll-like receptor 9 (TLR9) agonist as the adjuvant. The present invention further discloses the use of a CpG oligodeoxynucleotide that is a synthetic oligodeoxynucleotide comprising immunostimulatory unmethylated CpG motifs as the adjuvant. More specifically, a representative CpG oligodeoxynucleotide that can be used as an immunoadjuvant is CpG 7909 oligodeoxynucleotide. The TLR9 agonist or CpG oligonucleotide may be adminstered separated or conjugated together chemically as is known in the art. Furthermore, the present invention is drawn to the use of the immunogenic composition comprising dLPS-J5/OMP and CpG 7909 for the prevention and treatment of sepsis and infection with biodefense agents. In addition to the utility of the vaccine in preventing and treating sepsis, the present invention also contemplates its use in the prevention of infections caused by select agents. 
     Although there was a great interest in the use of anti-endotoxin antibodies in the 1970s and 1980s, clinical studies with monoclonal antibodies to lipid A were not successful. As a result, effort was focused on developing cytokine inhibitors and other inhibitors of inflammatory mediators. However, during the same time a killed, whole bacterial cell vaccine was made from  E. coli  J5 mutant and used for immunization of healthy volunteers. Sera from these immunizations when used in a clinical trial demonstrated that the post-immunization sera was highly protective in patients with Gram-negative bacterial sepsis. But this vaccine was never developed into a refined vaccine. Additionally, there are many experimental vaccines for sepsis that are being developed, but none of these have progressed to clinical trials. In fact, one such vaccine that requires incorporation of multiple lipopolysaccharide species into liposomes has not been used in clinical trials because of the difficulty in making it on commercially. Furthermore, although CpG oligodeoxynucleotides have been used as immunoadjuvant for some protein vaccines such as hepatitis B (Halperin et al., 2003; Cooper et al., 2005) and influenza A (Cooper et al., 2004) but never with a lipopolysaccharide. Recent studies have indicated that CpG oligodeoxynucleotide might also be used to stimulate polysaccharide antibody responses in  Haemophilus influenzae  type B conjugate vaccine (von Hunolstein et al., 2000) and the pneumococcal vaccine (Chu et al., 2000). 
     In distinct contrast, the vaccine disclosed by the present invention does not require complex preparation and discloses the ability of CpG oligodeoxynucleotides to enhance antibody response to lipopolysaccharide based vaccine. Mice were immunized with the dLPS-J5/OMP vaccine with or without the adjuvant. The vaccine-induced antibody response was examined in a cecal ligation and puncture model (CLP). This model generates a bacteremic infection by endogenous enteric bacteria and therefore, serves as clinically relevant test system. The mechanism of protection offered by the vaccine was further investigated in this experimental model. 
     Immunization with the dLPS-J5/OMP vaccine without the adjuvant resulted in &gt;20 fold increase in anti-core lipopolysaccharide antibody levels which was further increased 5 fold on addition of CpG oligodeoxynucleotide to the vaccine. The vaccine adjuvant combination was highly protective not only in the neutropenic rat model of sepsis but also in a model of polymicrobial sepsis, the CLP model in mice. In the CLP model, the vaccine adjuvant combination did not show a superior protection over vaccine alone since the protection with the vaccine alone was nearly 100%. However, evaluation of surrogate markers for vaccine effectiveness (cytokine, endotoxin level, bacterial loads) suggested that the vaccine adjuvant combination might be superior in a more severe model of sepsis. 
     For instance, circulating endotoxin levels and the quantity of gram-negative bacteria in organ cultures were significantly reduced by the vaccine administration. These results are compatible with the hypothesis that anti-core glycolipid antibodies bind to microbial antigens and are being cleared in vivo at a greater rate than other circulating immunoglobulins in animals with polymicrobial gram-negative sepsis. There was also a decrease in local inflammatory cytokine production within the peritoneum in immunized mice when compared to control animals. Lipopolysaccharide levels in the peritoneum were diminished albeit not significantly following active immunization with the vaccine. Anti-core glycolipid antibody levels were specifically depleted following CLP than total circulating IgG levels or IgG levels to the OMP part of the vaccine complex. This lack of comparable reductions in circulating immunoglobulin to OMP antigen argues against a generalized, non-specific decrease in antibody levels from increased catabolism, altered tissue distribution or decreased synthesis of immunoglobulins. These results in the CLP model support the previous findings with vaccine protection in the neutropenic rat model of sepsis with either  Pseudomonas aeruginosa  or  Klebsiella pneumoniae  (Bhattacharjee et al., 1996; Cross et al., 2001). Thus, the results obtained in the CLP model demonstrated that the detoxified LPS-J5/OMP vaccine induced high titer antibodies against the core glycolipid of lipopolysaccharide and functioned in vivo to promote clearance of gram-negative bacteria and improve the outcome in experimental, polymicrobial intra-abdominal sepsis. The results also showed that the efficacy of the vaccine could be improved when combined with CpG oligodeoxynucleotide. 
     Additionally, it was reported that boiled, whole bacterial vaccine prepared from  E. coli  J5 (Rc chemotype) O111:B4 elicited antibody in rabbits protected neutropenic rats from lethal gram-negative infection (Cross et al., 2004). Since affinity purified IgG prepared from this antisera was protective, a vaccine with detoxified lipopolysaccharide from  E. coli  O111:B4 (Rc chemotype mutant) was also developed (Cross et al., 2003). The detoxified  E. coli  J5 lipopolysaccharide was non-covalently complexed to group B meningococcal OMP to maintain a critical conformational epitope present in the native core glycolipid structure of lipopolysaccharide (Bhattacharjee et al., 1996). This vaccine, like the heat-killed bacterial vaccine, was protective in both active and passive models in the neutropenic rat model (Bhattacharjee et al., 1994). This protection was associated with both decreased levels of circulating cytokines, bacterial endotoxin and reduced concentrations of bacteria in target organs. 
     Based on the success in the use of this vaccine in the animal model, the vaccine was used in phase I clinical testing in normal human volunteers (Cross et al., 2003). The dLPS-J5 OMP vaccine was given in doses from 5-25 mcg (based upon its lipopolysaccharide content) to 24 volunteers in a three dose schedule from day 0 to day 28 and day 56. The vaccine was well tolerated with no significant systemic toxicity and no abnormal laboratory values attributed to the vaccine itself (Cross et al., 2003; Cross et al., 2004). Approximately two-thirds of these subjects experienced some mild to moderate pain at the injection site which usually resolved within 28-48 hours. Whereas preclinical studies in other mammals consistently demonstrated greater than 20 fold increases in antibody concentration, human volunteers had only a 3 fold increase over pre-immune baseline levels. Despite the rather modest increase in antibody levels, immune plasma from volunteers reduced cytokine generation in a whole blood assay (Cross et al., 2004). Since studies in the neutropenic rat model indicated the need for high levels of anti-core glycolipid antibody to offer protection (Bhattacharjee et al., 1994), an effort was undertaken to determine if immunoadjuvants would increase vaccine-induced antibody response. 
     The present invention demonstrated that addition of CpG oligodeoxynucleotides to the detoxified lipopolysaccharide vaccine resulted in a marked increase in anti-J5 LPS antibody responses (Table 1). For example, there was a 5 fold increase in the antibody concentration of IgG antibodies with the addition of CpG oligodeoxynucleotides to the vaccine. Each animal that received CpG oligodeoxynucleotides along with the vaccine had higher IgG levels than any animal in receipt of vaccine alone. While alum and CpG oligodeoxynucleotides have been used together and shown to have synergy in various preclinical vaccines, as well as for a hepatitis B vaccine in clinical testing (Halperin et al., 2003; Joseph et al., 2002; Malanchere-Bres et al., 2001) the addition of alum to this vaccine significantly reduced antibody responses to this vaccine (Table 1). This reduction in the antibody response could be due to blocking of the alignment and/or exposure of a critical conformational epitope in this vaccine that is normally recognized by the host immune system by alum when administered with CpG ODN. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 Immunization of mice (CLP model) with dLPS-J5/OMP 
               
               
                 vaccine with and without adjuvants 
               
            
           
           
               
               
               
               
            
               
                   
                   
                 IgG Level (ng/ml) 
                   
               
               
                   
                 Treatment 
                 (range) 
                 SEM 
               
               
                   
                   
               
            
           
           
               
               
               
               
            
               
                   
                 Vaccine a   
                   
                 3,253 
               
               
                   
                 11,259 
               
               
                   
                 (3,036-23,880) 
               
               
                   
                 Vaccine + CpG 
                 72,052* 
                 29,889 
               
               
                   
                   
                 (26,333-219,650) 
               
               
                   
                 Vaccine + Alum 
                 25,472  
                 9,306 
               
               
                   
                   
                 (5,522-54,355) 
               
               
                   
                 Vaccine + CpG + Alum 
                  6,197** 
                 828 
               
               
                   
                   
                 (4,380-8,976)  
               
               
                   
                 CpG + Alum 
                   85 
                 15 
               
               
                   
                   
                 (51-151) 
               
               
                   
                 Control 
                   60 
                 13 
               
               
                   
                   
                 (0-87) 
               
               
                   
                   
               
               
                   
                   a Vaccine refers to dLPS-J5/OMP vaccine; Mice (6/group) were immunized with vaccine (10 g, based on LPS content), CpG (25 g/mouse) or alum (10 g) as indicated at time 0, and days 14 and 28. Sera was obtained at day 35 and sera from individual mice were examined in an anti-J5 LPS ELISA.s); 
               
               
                   
                 *vaccine alone vs. vaccine + CpG-P &lt; .01; 
               
               
                   
                 **vaccine + CpG + alum vs. vaccine + CpG P &lt; .01 
               
            
           
         
       
     
     The adjuvant effect of CpG oligodeoxynucleotides was also evident in animals that underwent active immunization prior to the CLP procedure. Comparable with previous experiments, a prominent increase in the geometric mean concentration of anti-J5 dLPS IgG levels was attained after receiving a three dose series of immunizations and this provided a high level of protection. Since the protection observed with J5 vaccine alone was &gt;90%, it was difficult to show a survival advantage when the vaccine was given with CpG. 
     Additionally, the administration of a single dose of CpG given 6 days prior to CLP offered protection in mice from lethal sepsis as previously reported (Weighardt et al., 2000). This protection had been attributed to enhanced phagocytic function and immune clearance induced by CpGs. However, the administration of CpG oligodeoxynucleotide alone with the 3 dose vaccine schedule 30 days before CLP provided no survival benefit. The CpG oligodeoxynucleotide in the present invention appeared to function as an adjuvant for the vaccine with enhancement of adaptive immune responses and not as an independent non-specific stimulant of innate host defenses (Klinman, 2003; Gao et al., 2001). 
     Furthermore, the superior protective effect of the addition of CpG oligodeoxynucleotides in the CLP model compared with dLPS-J5/OMP vaccine alone could not be demonstrated ( FIG. 1 ). This may be due to the fact that the antibody response induced by the vaccine alone, even with its partial depletion during sepsis, produced antibody levels far in excess (mean core glycolipid antibody concentration-151 microgram/ml) of that required for protection. Both vaccine alone and vaccine plus CpG oligodeoxynucleotide groups had lower levels of local cytokines within the peritoneum and lower levels of bacteria found within organs following CLP. Despite both vaccine alone and vaccine+CpG oligodeoxynucleotide having high levels of anti-core glycolipid antibody, the lowest TNF concentration and lipopolysaccharide concentration was found in the vaccine group that received the CpG oligodeoxynucleotide immunoadjuvant. This suggested that with a higher level of sepsis severity, the addition of CpG oligodeoxynucleotide to the vaccine may provide better protection, especially in more severe models of severe sepsis and septic shock. 
     Furthermore, it was observed that the antibodies that were induced by the vaccine were capable of recognizing  Burkholderia pseudomallei  and  Francisella tularensis . In case of  Burkholderia , vaccine antibodies decreased the ability of the  Burkholderia  lipopolysaccharide to generate cytokines in human peripheral blood mononuclear cells. Hence, the functional activity of these antibodies are also demonstrated against tularemia and  Y. pestis , the agent of plague. Additionally, the protective ability of the vaccine with and without the CpG adjuvant was examined in a model of Gram-negative bacterial pneumonia when administered parenterally and intranasally. The vaccine with the CpG adjuvant was observed to be highly protective when the mice were challenged with  Klebsiella  after active immunization. Hence, the efficacy of the vaccine-adjuvant combination is also be demonstrated by challenging with  Pseudomonas  and other select agents. Further, the efficacy and the mechanism of action of the vaccine with and without the CpG adjuvant such as CpG 7909 is also examined in Phase I trial with human subjects. Since it appeared that the antibody facilitated the uptake and killing of bacteria by macrophages in vitro and promoted clearance of the bacteria and/or lipopolysaccharide from the circulation, the macrophage uptake assay will be used for rapid screening of either lots of antibody or the production of monoclonal antibodies. 
     Despite the above-discussed results, the mechanism of protection afforded by this vaccine has not been fully elucidated. Since there was a decreased bacterial load of aerobic organisms in the organs of immunized mice, one mechanism of protection of the vaccine may be the uptake and killing of bacteria by tissue phagocytes. Previous studies involving passive administration of anti-core glycolipid antibodies had shown that post-immunization sera promoted the clearance of both lipopolysaccharide and bacteria from the circulation (Cross et al., 2001). Thus, the present invention contemplates investigating whether this was a primary mechanism of protection of the vaccine so that surrogate markers for vaccine efficacy can be developed for the human vaccine project. Further, based on the results described herein, it is also contemplated that the vaccine-induced antibodies might promote clearance of  Bacteroides fragilis  or other anaerobic, gram-negative, enteric microflora as well. 
     In the case of pneumococcal immunization or hepatitis B immunization (Malanchere-Bres et al., 2001; Khan et al., 2004), it had been shown that functional assays, and not simple binding assays correlated with vaccine-elicited protection. Unlike the situation with these microbial pathogens where only a single activity (opsonization or neutralization) appeared to be of primary importance, the host response to bacterial lipopolysaccharide was considerably more complicated. There were a wide range of potential, clinically relevant activities initiated by this microbial mediator and it was difficult to predict which function was the most appropriate target for inhibition by antibody-induced by the vaccine. Hence, the effect of vaccine-induced antibody on lipopolysaccharide-induced activities will be systematically analyzed to identify assays that would correlate with vaccine-elicited protection. 
     Nevertheless, based on these results, the present invention contemplates using the vaccine to raise antibodies for passive protection of individuals with sepsis. Thus, patients suspected of sepsis could receive the antibodies in conjunction with standard therapy (e.g. antibiotics and supportive care). Additionally, as observed with experimental vaccines for  Klebsiella  and  Pseudomonas , active immunization of patients upon arrival to the Shock and Trauma center induced antibodies in the patients and healthy individuals, the present invention contemplates using this vaccine in the same manner to prevent development of sepsis during the hospitalization of such individuals. Thus, this vaccine could be administered to patients who will undergo elective abdominal, urologic or gynecologic surgery that have a high risk of sepsis. This vaccine could also be given to individuals who work in areas with a high risk of injury such as policeman, fireman, military, loggers. 
     Studies have shown protection with active and passive J5dLPS-OMP parenteral immunization against lethal heterologous monomicrobial and polymicrobial sepsis (Cross et al., 2001; Bhattacharjee et al., 1996; Opal et al., 2005) which was dependent on anti-CGL IgG antibodies (Bhattacharjee et al., 1994). The purpose of the present invention was (1) to assess whether the J5dLPS-OMP vaccine could elicit antibody responses in the respiratory tract by different routes of administration, (2) to determine if this CGL vaccine can protect against lethal heterologous GNB pneumonia, and (3) to identify a potential mechanism of action for antibodies elicited by the sepsis vaccine. 
     Only a few previous studies have examined the effect of i.n. immunization with glycolipid-based vaccines. Vaccines constructed from the detoxified LOS of nontypeable  Haemophilus influenzae  (Hirano et al., 2003) and  Moraxella catarrhalis  (Jiao et al., 2002) and non-detoxified LPS from  Brucella melitensis  (Bhattacharjee et al., 2002; Van d et al., 1996) and  Shigella flexneri  2a and  Shigella sonnei  (Orr et al., 1993) have shown enhanced clearance or protection from pneumonia with homologous bacterial species. A live attenuated  Salmonella  expressing the O antigen portion of LPS from  Pseudomonas aeruginosa  provided protection from heterologous strains of  P. aeruginosa  (DiGiandomenico et al., 2007). The present invention shows protection from heterologous bacterial species. 
     The results presented herein are consistent with the finding that i.n. delivery of glycolipid-based vaccines elicits both systemic and mucosal IgG and IgA, but parenteral delivery did not elicit a robust local IgA response. While there was no gross blood in the BALF which might indicate that systemic IgG from serum might have leaked inadvertently into the BAL samples during the lung washes, the possibility cannot be completely ruled out. If IgG is sufficient for protection from GNB pneumonia, then parenteral vaccination may be adequate. However, if secretory IgA is an important line of defense against pathogens of the respiratory mucosal lining, then i.n. or alternative mucosal routes of administration might provide a more protective immune response. 
     Secretory IgA is generally accepted as helpful in the clearance of pathogens in the gut and nasal mucosa; this is done primarily by “immune exclusion” (Brandtzaeg., 2007). However, secretory IgA does not fix complement nor induce phagocytosis in neutrophils or Kuppfer cells (Snoeck et al., 2006). No studies that definitively demonstrate that secretory IgA grants any protection in the lower respiratory tract are known so far. In fact, the protective antibody of the lower respiratory tract is believed to be serum IgG (Brandtzaeg, 2007; Renegar et al., 2004). Furthermore, IgA deficiency is one of the most common primary immunoglobulin deficiencies yet most individuals are clinically asymptomatic. These data argue against a role for IgA as a protective factor in pneumonia. 
     Using the model of lethal heterologous GNB pneumonia, the present invention demonstrated a survival benefit with active i.n. immunization of J5dLPS-OMP with CpG compared to control animals, using an outbred strain of mice. The present invention also showed significant differences in severity of pneumonia, as assessed by weight loss, between i.n. vaccinated and control mice.  Klebsiella pneumonia  O1:K2 was used as the challenge organism because its high virulence (Cross et al., 1993). The ICR mice were challenged by IT route of administration with  Pseudomonas aeruginosa  isolates PA01 and PA12.4.4, doses in excess of 10 8  CFU failed to achieve 50% lethality. Therefore, the in vivo vaccination protection studies were not performed with  Pseudomonas  because the animal model would more likely reflect a model of endotoxemia rather than pneumonia. 
     In the present invention, CpG was used as a potential immunostimulatory adjuvant for the J5dLPS-OMP vaccine. The specific dinucleotide motifs in these chemically synthesized sequences are known to stimulate antigen presenting cells via Toll-like receptor 9 and are optimized for each animal species. These CpG ODN have been shown to significantly enhance systemic and mucosal immune responses to protein vaccines, such as purified hepatitis B surface antigen, when given mucosally (McCluskie and Davis, 1999). On the other hand, CpG ODN can activate non-specific innate immune responses resulting in protection from lethal bacterial challenges, yet these systemic responses wane rapidly (Wongratanacheewin et al., 2004; Elkins et al., 1999; Klinman et al., 1999) and persist less than 10 days when administered via the respiratory tract (Deng et al., 2004; Nichani et al., 2007). The improved survival from pneumonia in mice that received vaccine and CpG i.n. are not likely the result of non-specific responses from CpG since our mice were administered the last dose of CpG at least 2 weeks prior to challenge. 
     The present invention identified a correlation with decreased organ loads in protection from lethal challenge and enhanced killing of both  Klebsiella pneumoniae  and  Pseudomonas aeruginosa  with primary macrophages which seems to be based on the antibodies elicited by the vaccine. An alternative explanation for the modest but significantly enhanced in vitro bactericidal activity is the nonspecific, non-macrophage enhancement of antibacterial lung defenses (Laforce et al., 1980). The increased colony counts with addition of L-NIL, which blocks nitric oxide production and is a critical antibacterial effector in phagocytes, confirms that macrophage-mediated killing was probably responsible for the differences in viable bacterial counts in our assay. Since protection from an infection can be achieved against a number of mucosal pathogens with the elicitation of high levels of serum IgG (Robbins et al., 1995; Robbins et al., 1992), the magnitude of BALF anti-CGL IgG elicited by parenteral administration of the CGL vaccine might obscure the contribution of local anti-CGL IgA antibodies produced by i.n. vaccination. The reduction in killing with the dilution of serum 1000-fold does not rule out the possibility of non-Ig, non-complement opsonins as the reason for enhanced in vitro killing. 
     Resident AM differ from other macrophages, such as PM, in that they are capable of ingesting large quantities of foreign particulate while remaining relatively quiescent and avoiding the potential for collateral tissue damage by the elaboration of pro-inflammatory responses in the lung (Martin and Frevert, 2005). However despite those differences, the present invention shows that AM were similar to PM in their ability to kill opsonized PAO1 in vitro. 
     In conclusion, the ability of this vaccine to protect against lethal heterologous GNB pneumonia either by mucosal IgA and/or systemic and mucosal IgG following intranasal or parenteral routes of administration warrants further investigation. 
     The present invention also examined the effect of the vaccine disclosed herein against biological threat agent such as the Gram-negative bacteria,  Francisella  tularensis, which is an agent of tularemia. In this study, the mice were immunized with the vaccine with and without the CpG adjuvant and the effect of the vaccine compared between vaccine-immunized mice and control mice. There was no difference between vaccine alone and vaccine+CpG and hence were grouped together as vaccinated ( FIG. 11 ). In contrast, immunization with the vaccine protected the mice from lethal inhalational tularemia. The present invention demonstrates that intranasal immunization with J5dLPS/OMP vaccine+CPG protected mice from lethal pulmonary infection with LVS and in initial experiments with the more virulent type A strain SchuS4. Given the decreased bacterial organ load, vaccine induced antibodies may have enhanced phagocyte killing of FT but this must be directly examined. Decreased tissue cytokines may reflect reduced bacterial load in immunized mice. Since the LPS of FT differs from that of other gram negative bacteria, the epitope on FT recognized by vaccine-induced antibodies is not clear. While CPG stimulates innate immune mechanisms, its effect usually wanes by 7 days, well before the i.t challenge and cannot explain the observed protection. The methods and compositions of the present invention would also be useful against other Gram negative bacteria such as  Yersinia pestis , the agent of plague. 
     Furthermore, if the vaccine is found to be effective in preventing or ameliorating infection following exposure to some select agents, then it could also be used to counter bioterrorism. As discussed above, the vaccine without the CpG adjuvant has already been safely administered to humans in a phase I trial. However, there is a considerable evidence that endotoxin leakage from the gut to the circulation may play a role in heat-related injury and in graft-versus-host disease in stem cell transplantation. If this is true, then this vaccine can be given to prevent potentially lethal complications of these conditions. 
     The concentration of the lipopolysaccharide vaccine in the immunogenic composition may be from about 5 μg to about 50 μg. Specifically, the concentration may be about 5 μg-10 μg; 10 μg-15 μg; 15 μg-20 μg; 20 μg-25 μg; 25 μg-30 μg; 30 μg-35 μg; 35 μg-40 μg; 40 μg-45 μg and 45 μg-50 μg. The concentration of TLR9 agonist in the immunogenic composition is about 250 μg-500 μg. Specifically, the concentration may be about 250 μg-30 μg; 30 μg-350 μg; 350 μg-400 μg; 400 μg-450 μg and 450 μg-500 μg. The dose at which the antibody may be administered to the individual may be from about 100 mg/kg-1500 mg/kg. Specifically, the dose may be 100 mg/kg-200 mg/kg; 200 mg/kg-300 mg/kg; 300 mg/kg-400 mg/kg; 400 mg/kg-500 mg/kg; 500 mg/kg-600 mg/kg; 600 mg/kg-700 mg/kg; 700 mg/kg-800 mg/kg; 800 mg/kg-900 mg/kg; 900 mg/kg-1000 mg/kg and 1000 mg/kg-1500 mg/kg. Of course, all of these amounts are exemplary, and any amount in-between these points is also expected to be of use in the invention. 
     Treatment methods will involve preventing an infection in an individual with an immunologically effective amount of a composition containing lipopolysaccharide vaccine and a TLR9 agonist or an antibody generated using the immunogenic composition. An immunologically effective amount is described, generally, as that amount sufficient to detectably and repeatedly induce an immune response so as to prevent, ameliorate, reduce, minimize or limit the extent of a disease or its symptoms. More specifically, it is envisioned that the treatment with the immunogenic composition enhances antibody response, reduces the level of inflammatory cytokines and the levels of endotoxins and decreases the bacterial load in the individual to prevent the infection caused by the Gram-negative bacteria. 
     The immunologically effective amount of the immunogenic composition or antibody generated thereof to be used are those amounts effective to produce beneficial results, particularly with respect to preventing the infection caused by the Gram-negative bacteria, in the recipient animal or patient. Such amounts may be initially determined by reviewing the published literature, by conducting in vitro tests or by conducting metabolic studies in healthy experimental animals. Before use in a clinical setting, it may be beneficial to conduct confirmatory studies in an animal model, preferably a widely accepted animal model of the particular disease to be treated. Preferred animal models for use in certain embodiments are rodent models, which are preferred because they are economical to use and, particularly, because the results gained are widely accepted as predictive of clinical value. 
     The immunogenic composition disclosed herein and the antibody generated thereof may be administered either alone or in combination with another drug, a compound, or an antibiotic. Such a drug, compound or antibiotic may be administered concurrently or sequentially with the immunogenic composition or antibody disclosed herein. The effect of co-administration with the immunogenic composition or antibody is to lower the dosage of the drug, the compound or the antibiotic normally required that is known to have at least a minimal pharmacological or therapeutic effect against the disease that is being treated. Concomitantly, toxicity of the drug, the compound or the antibiotic to normal cells, tissues and organs is reduced without reducing, ameliorating, eliminating or otherwise interfering with any cytotoxic, cytostatic, apoptotic or other killing or inhibitory therapeutic effect of the drug, compound or antibiotic. 
     The composition described herein and the drug, compound, or antibiotic may be administered independently, either systemically or locally, by any method standard in the art, for example, subcutaneously, intravenously, parenterally, intraperitoneally, intradermally, intramuscularly, topically, enterally, rectally, nasally, buccally, vaginally or by inhalation spray, by drug pump or contained within transdermal patch or an implant. Dosage formulations of the composition described herein may comprise conventional non-toxic, physiologically or pharmaceutically acceptable carriers or vehicles suitable for the method of administration. 
     The immunogenic composition or antibody described herein and the drug, compound or antibiotic may be administered independently one or more times to achieve, maintain or improve upon a therapeutic effect. It is well within the skill of an artisan to determine dosage or whether a suitable dosage of either or both of the immunogenic composition or antibody and the drug, compound or antibiotic comprises a single administered dose or multiple administered doses. 
     As is well known in the art, a specific dose level of such an immunogenic composition or antibody generated thereof for any particular patient depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. The person responsible for administration will determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards. 
     One of skill in the art realizes that the immunologically effective amount of the immunogenic composition or the antibody generated thereof can be the amount that is required to achieve the desired result: enhance antibody response, reduce the level of inflammatory cytokines and levels of endotoxins, decrease the bacterial load, etc. 
     Administration of the immunogenic composition of the present invention and the antibody generated thereof to a patient or subject will follow general protocols for the administration of therapies used in treatment of bacterial infections taking into account the toxicity, if any, of the components in the immunogenic composition, the antibody and/or, in embodiments of combination therapy, the toxicity of the antibiotic. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies, as well as surgical intervention, may be applied in combination with the described therapy. 
     As is known to one of skill in the art the immunogenic composition described herein may be administered along with any of the known pharmacologically acceptable carriers. Additionally the immunogenic composition can be administered via any of the known routes of administration such as subcutaneous, intranasal or mucosal. Furthermore, the dosage of the composition to be administered can be determined by performing experiments as is known to one of skill in the art. 
     The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art. 
     Example 1 
     Vaccine Antigen and Vaccine Adjuvant 
     The rodent-specific CpG ODN (# 1826) was procured from Coley Pharmaceutical Group (Wellesley, Mass.). The dLPS-J5/OMP vaccine was developed in a GMP facility (Cross et al., 2003). The meningococcal OMP was derived from lipopolysaccharide-free, membrane-free proteosomes and complexed with detoxified  E. coli  J5 LPS. 
     Example 2 
     Assays and Reagents 
     Murine cytokine and chemokine levels were measured using the BioPlex 16 multiplex cytokine assay (Bio-Rad, Hercules, Calif.). LPS levels were measured using a quantitative turbidimetric  Limulus Amebocyte  lysate assay, (Associates of Cape Cod Woods Hole, Mass.). All other reagents and chemicals were provided by Sigma (St. Louis, Mo.) unless otherwise stated. 
     Example 3 
     Cecal Ligation and Puncture Model 
     Pathogen-free albino, female BALB/c mice (Charles River Laboratories, Cambridge, Mass.) were used in the experiments. The animals were 8-12 weeks of age and were allowed to adapt to the laboratory for seven days before any experiments were initiated. The animals were allowed to eat and drink ad libitum. 
     The experimental design was modeled after previously published investigations (Opal et al., 2001). After an overnight fast, animals were anesthetized with parenteral administration of 200 microliter intraperitoneal injection of ketamine-9 mg/ml (Abbott, North Chicago, Ill.) and xylazine-1 mg/ml (Phoenix Pharmaceuticals, St. Josephs, Mo.). Under sterile conditions a midline abdominal incision was made and the cecum was identified and exteriorized. The cecum was then ligated with a 4-0 monofilament ligature and the ante-mesenteric side of the cecum was punctured twice with a 23 gauge needle. A scant amount of luminal contents was expressed through each puncture site to assure patency. The cecum was then returned to the abdomen and the fascia and skin was closed in two layers. 
     Lidocaine (1% without epinephrine) was applied to the surgical site along with topical antibiotic (bacitracin). A single I.M. dose of trovafloxacin (Pfizer, New York) (20 mg/kg) was administered along with 1.0 ml of normal saline subcutaneously. The animals were warmed externally until they were able to regain normal mobility. Mortality was monitored over seven days. Moribund animals that were unable to right themselves and were hypothermic (&lt;33° C. by digital infrared thermometry) were euthanized and considered lethally infected. Each animal underwent necropsy examination where liver and spleen tissues were removed for quantitative organ cultures on MacConkey media and  enterococcus -specific media (BBL, Cockeysville, Md.). A 1 ml sample of peritoneal fluid was obtained following a lavage of the peritoneum with 5 ml of normal saline at the time of autopsy. 
     Example 4 
     Vaccine Schedule 
     The dJ5LPS/OMP vaccine was administered at 10 μg or 20 μg (based on dLPS content) intramuscularly at 0, 2 and 4 weeks. After a one month rest period, the CLP was performed. Blood samples were collected at baseline, one month after the final immunization and before CLP and then 48 hours after CLP. The CpG oligodeoxynucleotides immunoadjuvant (25 μg/mouse) was administered admixed with the vaccine in the same syringe. The control group received CpG oligodeoxynucleotides with saline at the same dose and time schedule. As an additional control, CpG oligodeoxynucleotides was administered to a separate set of animals (n=5) at 25 μg/animal 6 days prior to the CLP since previous study (Weighardt et al., 2000) had indicated that CpG alone may have significant immunoprophylactic effects when administered shortly before major systemic insults. Antibody levels to core glycolipid structures were measured using a standard ELISA method (Cross et al., 2003). 
     Example 5 
     Statistical Analyses 
     Numeric data was analyzed by a non-parametric Kruskal-Wallis one way analysis of variance with Dunn&#39;s multiple comparisons test for multiple groups of mice or Mann-Whitney U test for two groups of mice. A Kaplan-Meier survival plot was used to analyze outcome in each treatment group and differences in survival time were measured by the log-rank test. A paired Student&#39;s t-test was used to measure antibody levels and ratios of antibody response. A probability of &lt;0.05 was considered significant. 
     Example 6 
     Immunogenicity of dLPS-J5/OMP Vaccine with or without Adjuvant 
     The ability of the vaccine constructs to induce antibody responses is summarized in Table 1. Antibody responses were tested after three doses of 10 mg of the vaccine administered 14 days apart as an intramuscular injection. The antibody response to dLPS-J5/OMP alone, with CpG oligodeoxynucleotides, with alum and a combination of CpG oligodeoxynucleotides and alum were investigated. As previously reported (Cross et al., 2001) the dLPS/OMP vaccine alone was highly immunogenic (P&lt;0.005 versus control group) and well tolerated. The mean antibody concentration was increased 5 fold (P&lt;0.01) by CpG oligodeoxynucleotides. Alum produced a modest increase in the antibody response to the dLPS-J5/OMP vaccine alone but significantly reduced the antibody response to the combination of CpG oligonucleotides plus dLPS-J5/OMP vaccine (P&lt;0.01). Since this reduction in antibody response could be due to interference of alum with epitope processing of the vaccine construct when adminstered along with CpG oligodeoxynucleotides, alum was not used in the vaccine preparation in subsequent studies. 
     Example 7 
     Active Protection with dLPS-J5/OMP Vaccine with and without CpG ODN 
     Animals (n=15/group) were actively immunized in the presence or absence of CpG oligodeoxynucleotides. The control group (n=5) received CpG oligodeoxynucleotides+saline administered at the same time interval completing the immunization schedule 30 days before CLP. 
     The results of the CLP experiment are presented in  FIG. 1 . A second control group received CpG oligonucleotides alone six days prior to CLP (n=5). The dLPS-J5/OMP vaccine group with or without CpG oligodeoxynucleotides provided significant protection from lethality following CLP (P&lt;.0.1). When given 6 days before CLP, CpG oligodeoxynucleotides provided some protection (4/5 animals survived) but when given alone at the same schedule as the immunizations (i.e. last dose given one month before CLP), there was no survival in this control group ( FIG. 1 ). 
     Serum IgG levels against core LPS were measured 28 days after the final immunization (pre-CLP) and 48 hours following CLP ( FIG. 2 ). While the 20 mg dosing regimen of the dLPS-J5/OMP vaccine alone was highly immunogenic (mean IgG level of anti-core antibody at 151 g/ml), the co-administration of the vaccine with CpG oligonucleotides increased the antibody titer approximately 3-5 fold to 552 g/ml (P&lt;0.005 vs. dLPS-J5/OMP vaccine alone). The CpG-oligodeoxynucleotides control group had a flat antibody response with anti-core antibody levels remaining at baseline values of 0.12 g/ml. The CpG+saline control group all succumbed to polymicrobial intra-abdominal sepsis following CLP ( FIG. 1 ). The dLPS-J5/OMP vaccine group with or without CpG oligodeoxynucleotides were highly protected from lethality after CLP (P&lt;0.01). 
     The plasma lipopolysaccharide levels were significantly lower in the dLPS-J5/OMP vaccine groups with or without CpG oligonucleotides and peritoneal lipopolysaccharide levels trended lower in the vaccine groups compared to the control group (Table 2). Bacterial concentrations in organ samples were reduced in the vaccine groups compared to the control group. Peritoneal, but not plasma, TNF levels were significantly reduced following CLP in the vaccine group (P&lt;0.01). Gram-negative bacterial counts, TNFa and LPS levels within the peritoneum were lowest in the vaccine+CpG oligodeoxynucleotides group but were not sufficiently different from values measured in the dLPS-J5/OMP vaccine group to reach statistical significance (Table 2). 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Active Immunization of mice (CLPmodel) 
               
               
                 with anti-core glycolipid vaccine 
               
            
           
           
               
            
               
                 P value* 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 Plasma endotoxin 
                 7.75.5 
                 0.20.12 
                 1.81.6 
                 &lt;.001 
               
               
                 (ng/ml) 
               
               
                 Plasma TNF** (pg/ml) 
                 32.010 
                 11.67.9 
                 18.15.8 
                 ns 
               
               
                 Organ cultures 
                 350774 
                 4097 
                 031 
                 &lt;.05 
               
               
                 (CFU/mg) 
               
               
                 Peritoneal TNF (pg/ml) 
                 52.63.0 
                 23.36 
                 15.04.5 
                 &lt;.01 
               
               
                 Peritoneal endotoxin 
                 92.444 
                 10.632 
                 3.19 
                 0.1 
               
               
                 (ng/ml) 
               
               
                   
               
               
                 P values represent differences (mean +/− sem) between control vs. either vaccine group (with or without CpG-ODN&#39;s). No significant differences were found between the two vaccine groups 
               
            
           
         
       
     
     If a mechanism of action of the anti-core glycolipid antibodies was to bind and promote the clearance of bacteria by the reticulo-endothelial system, then serum antibodies against core glycolipid and not anti-OMP antibodies would be decreased. This depletion of anti-core glycolipid antibody could be due to a generalized decrease in IgG (e.g. hypermetabolic state during sepsis) or to a depletion in specific antibody (as may occur with the binding of antigen and subsequent clearance of the complex). Although a brisk antibody response to the OMP component of the vaccine complex was observed following immunization, the levels of IgG specific for OMP 48 hr post CLP was only mildly reduced (1-2 fold pre-CLP levels). This level of reduction in IgG specific for OMP was comparable to the ratio of total IgG levels before and after CLP ( FIG. 2 ). 
     In contrast, serum anti-core lipopolysaccharide IgG levels were significantly depleted 3-4 fold 48 hours after onset of intra-abdominal sepsis. This reduction in antibody levels was specific for the target epitopes found within the core oligosaccharide portion of the vaccine formulation. As expected the administration of CpG oligodeoxynucleotides alone at the same vaccine schedule induced minimal IgG antibody responses to either OMP or core glycolipid. 
     Example 8 
     Protection Against Select Agents with dLPS-J5/OMP Vaccine with CpG ODN 
     The antibody induced by the vaccine of the present invention bound to both the LPS of the various select agents ( FIG. 3B ) shown in the figure as well as to the whole bacteria ( FIG. 3A ). In the ex vivo assay ( FIG. 4A ), the various LPS preparations were added to heparinized human whole blood, incubated the mixture overnight and then measured cytokine levels in the plasma. The effect on cytokines induced by  Burkholderia  (the agent of melioidosis) was quite substantial. There was no effect on the LPS of  francisella  since that LPS had very limited endotoxic activity (if any). The present invention also showed that the antibody induced by the vaccine bound to a highly antibiotic-resistant strain of actinobacter, which has been the scourge of ICU units nationwide, and has forced clinicians to use old, highly toxic antibiotics. The present invention also demonstrated the effect of the various combinations of the vaccine preparations on the serum and the BAL IgA and IgG levels (Table 3;  FIGS. 4B-E ). Additionally, the present invention also demonstrated the effect of the vaccine after intratracheal challenge ( FIG. 5 ). The vaccine and CpG construct was immunoprotective when mice were challenged with  K. pneumoniae . 
     
       
         
           
               
             
               
                 TABLE 3 
               
             
            
               
                   
               
               
                 Effect of the Vaccine preparations on the Serum and BAL IgG an dIgA levels. 
               
            
           
           
               
               
               
            
               
                   
                 Serum 
                 Bal 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                   
                 N 
                 IgG(μg/ml) 
                 %* 
                 IgA (OD**) 
                 %* 
                 IgG(μg/ml) 
                 %* 
                 IgA (OD**) 
                 %* 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
            
               
                 IN J5 
                 10 
                  6.6 ± 2.1 
                 70 
                 0.48 ± 0.20 
                 30 
                 0.06 ± 0.02 
                 30 
                 0.45 ± 0.15 
                 40 
               
               
                 IN J5 + CpG 
                 10 
                   13 ± 7.1 
                 90 
                 0.63 ± 0.20 
                 50 
                 0.36 ± 0.20 
                 30 
                 0.57 ± 0.17 
                 60 
               
               
                 IP J5 
                 7 
                 1000 ± 560 
                 100 
                 0.12 ± 0.01 
                 0 
                 14 ± 10 
                 86 
                 0.50 ± 0.22 
                 29 
               
               
                 IN J5 + CpG 
                 7 
                 2300 ± 470 
                 100 
                 0.14 ± 0.02 
                 0 
                 60 ± 43 
                 100 
                 0.20 ± 0.02 
                 0 
               
               
                 IN CpG 
                 4 
                  0.03 ± 0.002 
                   
                 0.11 ± 0.01 
                   
                 0.03 ± 0.01 
                   
                 0.10 ± 0.01 
               
               
                   
               
               
                 Antibody levels expressed as mean ± standard error. 
               
               
                 *% responders with antibody titers ≧ 4x control (IN CpG) 
               
               
                 **OD is optical density of neat serum at A450 nm 
               
            
           
         
       
     
     Example 9 
     Protection Against Heterologous Gram-Negative Bacterial Pneumonia by Intranasal Administration of a Detoxified Endotoxin Vaccine 
     The vaccine used in all experiments was the previously characterized J5dLPS-OMP, containing 100 μg/ml of LPS and 136 μg/ml of OMP by weight (Cross et al., 2001). The adjuvant CpG ODN 2006 was obtained from Coley Pharmaceutical Group (Ottawa, Canada). The highly virulent  Klebsiella pneumoniae  O1:K2 strain was originally obtained from Drs. Ida and Frits Orskov, WHO  E. coli  and  Klebsiella  Reference Center (Statens Seruminstitut, Copenhagen, Denmark); the LD 50  in outbred ICR mice was ˜1×10 4  CFU. The  Pseudomonas aeruginosa  (strain PA01) was obtained from Dr. Gerald B. Pier (Boston, Mass.). 
     Mouse Vaccination 
     Female outbred white mice (Cr1:CD-1(ICR)BR, 6-8 week old, Charles River, Wilmington, Mass.) were vaccinated with 1 μg of J5dLPS-OMP (by LPS weight) either i.n. or i.p. on weeks 0, 2, and 4. The i.n. administration of 25 μg CpG preceded i.n. vaccination with J5dLPS-OMP by 30 minutes to one hour to allow mucosal absorption. The i.n. administration of saline, CpG, or J5dLPS-OMP was given in a liquid volume of 5 μl into each nostril (10 μl total volume). The i.p. vaccinations were given as a single injection in a total volume of 200 μl. All dilutions were performed with sterile endotoxin-free PBS (Biosource International, Rockville, Md.). All experiments were approved by and conducted in compliance with the Institutional Animal Care and Use Committee of the University Of Maryland School Of Medicine. 
     Mouse Pneumonia Model 
     The day prior to challenge, frozen bacteria, stored in 10% casein stocks at −20° C., were streaked onto trypticase soy agar (TSA) plates and incubated overnight at 37° C. On the day of challenge, single colony isolates were grown to mid-log phase in trypticase soy broth (TSB) at 37° C. on orbital shaker prior to washing and resuspending the cell pellet in sterile PBS to the desired challenge concentration. The actual inoculum of the challenge dose was confirmed by colony counts on TSA plates. 
     After at least two weeks from the last vaccination lethal doses of a previously described  Klebsiella  O1:K2 (Trautmann et al., 1994) were administered by a tongue-pull method to the lower respiratory tract (i.e. intratracheal (IT) route). Mice were anesthetized with isoflurane (Baxter; Deerfield, Ill.) prior to the deposition of 50 μl bacterial suspension to the posterior oropharynx. A successful challenge was confirmed by aspiration of the bacterial suspension and audible crackles. This method allowed us to deliver a consistent inoculum to each mouse. Each mouse was weighed daily until death or until they ceased to lose weight over 2 consecutive days and demonstrated signs of improvement (e.g. increased activity). Those still surviving at 14 days were euthanized and bacterial organ counts were performed. The peak percent weight loss for each mouse was calculated from the lowest post-challenge weight, prior to recovery or death, and the initial weight the day of the IT challenge. 
     Serum and BALF 
     In separate prospectively designated mice, serum and bronchioalveolar lavage fluid (BALF) was obtained two weeks after the third vaccination (day 42). Whole blood was obtained by cardiac puncture, after euthanization, and serum was stored at 4° C. The collection of BALF was performed by cannulation of the trachea and gentle lavage of the lungs with a single round of 1 ml sterile PBS. Both serum and BAL fluid were stored at 4° C. until analysis was performed, usually within 1 week. 
     ELISA for Anti-CGL Antibody 
     Serum and BALF samples were measured for anti-CGL IgG and IgA antibody levels as described (Bhattacharjee et al., 1994). ELISA IgG antibody titers were calculated from a standard curve created from mouse monoclonal IgG antibody (Sigma) when comparing the optical density at A 450  from the linear portion of the curve. ELISA IgA antibody titers were expressed as optical density units (ODU) calculated by multiplying the dilution factor by the optical density at A 450  from the linear portion of the curve. Values were considered non-detectable (ND) if they were below the limits of detection for the assay (&lt;10 ng/ml). A vaccine “responder” was defined as an antibody level that was ≧4 times that of the control. 
     Macrophage Killing Assay 
     Macrophages were cultured according to our previously described methods (Kang et al., 2005). Primary peritoneal macrophages (PM) were obtained from naive ICR mice 4 days after i.p. inoculation of 3% Brewer Modified Thioglycollate Medium (Becton Dickinson, Cockeysville, Md.). Alveolar macrophages (AM) were obtained from matched naïve ICR mice after four rounds of flushing the lungs with 1 ml PBS. In our hands, the recovered cells typically consisted of &gt;98% viability by Trypan Blue Dye exclusion and &gt;95% macrophages as determined by immunofluorescence using the F4/80 macrophage marker. (Lu et al., 2006) Peritoneal or BAL fluid cell suspensions from mice were pooled and adjusted to 1×10 6  macrophages per ml in culture medium containing RPMI-1640 (Gibco-BRL, Frederick, Md.) with 5% fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, Ga.), and rested in polypropylene tubes (Elkay Products, Inc. Shrewsbury, Mass.) in 5% CO 2  at 37° C. overnight. 
     Bacterial suspensions were freshly made from frozen stocks for each experiment as in the mouse pneumonia experiments. Bacteria, between 10 5 -10 6  CFU/ml, were opsonized by incubating at 4° C. for 30 min on rotator with an equal volume of un-diluted immune serum, immune BALF, control BALF, or sterile PBS (mock treatment). Macrophage-mediated killing by nitric oxide production was inhibited with 1 uM L-N 6 -(1-iminoethyl)lysine (L-NIL, Sigma). To determine macrophage-mediated killing at different time points, individual tubes containing infected macrophages were centrifuged at 380×g for 10 minutes after incubation for 1, 5, and 24 hours. Cells were lysed with 1 ml of cold sterile distilled water at 37° C. for 30 min, vortexed, and plated on TSA for the viable bacterial counts. The killing activity was measured by calculating the log difference in counts from time 0 to 1, 5 and 24 hours. 
     Statistical Analysis 
     Antibody ELISA results for both serum and BAL were expressed as arithmetic means with the standard error. Differences were analyzed by a non-parametric Kruskal-Wallis one-way analysis of variance for comparison of multiple groups or the Mann Whitney test for comparison of two groups. The survival functions of each vaccination group were expressed using Kaplan-Meier survival plots, and differences in survival were compared using the Logrank test. Macrophage-mediated log reductions were analyzed by the Student&#39;s t test. Results were considered significant with two-sided P values &lt;0.05. GraphPad Prism version 4.0 (San Diego, Calif.) was used to perform these statistical calculations. 
     Results 
     Following immunization, all mice demonstrated similar weight gain and had no overt adverse effects over 6 weeks. Mice immunized with i.n. CpG alone had anti-CGL antibody levels that were near the limits of detection of the assay. Mice immunized with PBS alone also had anti-CGL antibody levels that were near the limits of detection [DNS]. All mice that received i.p. vaccination had robust systemic IgG responses, regardless of whether CpG was used. Mice vaccinated with J5dLPS-OMP plus a single dose of CpG via the i.p. route showed statistically higher systemic (serum) anti-CGL IgG antibody titers than mice that were similarly vaccinated via the i.n. route ( FIG. 6A ). When J5dLPS-OMP was administered i.n., alone or with CpG, mice achieved a mean serum IgG antibody level approximately 100-fold lower than that achieved by i.p. vaccine administration (without CpG). The addition of CpG resulted in a doubling of serum IgG antibody regardless of the route of administration. Therefore, a single dose of CpG in a multi-dose immunization regimen modestly increased the antibody response. 
     When examining BALF, i.p. vaccinated mice likewise had significantly higher IgG antibody levels than i.n. immunized mice ( FIG. 6B ). Unlike the doubling observed in serum, the addition of CpG resulted in a 4-fold increase in BAL IgG antibody response when the vaccine was administered by either route. The i.p. route of administration resulted in 86-100% BALF IgG responders in comparison to 30% responders when delivered by the i.n. route of administration. 
     Since IgA might be important as a first line of defense against mucosal infections, such as GNB pneumonia, we measured the anti-CGL IgA antibody levels in both the serum and BAL fluid samples after immunization by both routes of administration. Mice that received J5dLPS-OMP i.p. alone had little serum anti-CGL IgA and the addition of CpG had did not increase the serum IgA antibody responses ( FIG. 6C ). In comparison, mice that were given J5dLPS-OMP by i.n. route of administration had modest serum IgA antibody responses; there was a trend toward higher IgA responses with the addition of CpG but this did not achieve statistical significance. 
     The BAL IgA for mice that were immunized i.p. with J5dLPS-OMP alone or with CpG was lower than mice that received vaccination by i.n. route of administration ( FIG. 6D ). Two of 7 mice that received i.p. vaccine alone had elevated IgA antibodies, but none of 7 mice that received i.p. vaccine plus CpG had elevated IgA antibodies. Thus, i.n. vaccination is superior to i.p. vaccination for the induction of IgA antibody responses. 
     Since a single dose of CpG was an effective immunoadjuvant for our vaccine, we speculated that concomitant administration of CpG with each of the three doses of J5dLPS-OMP might increase the chance for each mouse to mount local and systemic antibodies. However, we found that two or three doses of CpG compared to a single dose did not significantly improve either serum or BAL IgG and IgA anti-CGL responses when given by intramuscular, subcutaneous, or intraperitoneal routes of administration (DNS). 
     A murine model of pneumonia, using the tongue-pull IT route of administration, was used to evaluate whether i.n. vaccination with J5dLPS-OMP might be effective in protection against lethal GNB pneumonia. We consistently observed 100% lethality with  Klebsiella  O1:K2 in ICR mice at doses ≧10 6  CFU, &gt;80% lethality at 10 5  CFU, 50% lethality at just under 10 4  CFU, and no lethality at 10 3  CFU. Therefore the target dose for challenge experiments was ˜5×10 4  CFU, the linear portion of the lethality curve. Using this target dose in outbred mice resulted in progressive illness over 96 hours with death typically occurring between 5 and 8 days post-challenge. This  Klebsiella  isolate rapidly multiplied in vivo; predictably 10 6  CFU per gram of lung tissue and 100-1000 CFU per ml of blood were recoverable within the first 24 hours after infection. At 96 hours post-infection mice had 10 7  CFU per gram of lung tissue, 10 4 -10 5  CFU per ml of blood, and 10 5 -10 6  CFU per gram of extra-pulmonary tissue (i.e. liver and spleen). 
     In two separate challenge experiments, mice were immunized with 3 i.n. doses of J5dLPS-OMP plus CpG and compared to administering PBS alone and all mice were challenged ≧2 weeks later. In pilot studies mice vaccinated with CpG alone failed to demonstrate a survival benefit compared to saline (DNS). Two weeks after the third vaccination, IT challenges with  Klebsiella  O1:K2 at 5.8 and 6.3×10 4  CFU/mouse were performed in the two experiments, respectively. Vaccinated mice showed improved survival when compared to control mice (p=0.015, Logrank test) ( FIG. 7 , top). All surviving mice had complete clearance of bacterial infection as documented by the absence of culturable bacteria from the lungs and at distal sites at 10 days post-challenge, except for a single well-appearing mouse from the vaccinated group which at sacrifice was found to have 9×10 6  CFU/ml in the lung, 2700 CFU/ml from spleen and no bacteria recovered from the liver. All mice that died had very high organ bacterial counts, &gt;10 8  CFU per gram of tissue. The severity of pneumonia, as assessed by change in weight, trended toward less weight loss in the vaccinated mice ( FIG. 7 , bottom). Note that in order to graph some censored data, the weights of mice that died after the date of death were plotted using the weight at death; by day 8 post-challenge in the control group only 3 surviving mice contribute to the curve. The peak percent weight loss was calculated to compare the changes in weight, of each group, irrespective of whether individual mice lived or died. Mice immunized i.n. had 15.9% (95% CI 10.1-21.7) peak percent weight loss in comparison to 20.9% (95% CI of 16.1-25.5) in the control (PBS) group; not statistically different. 
     To assess whether i.n. vaccination might be superior to i.p., we immunized mice i.n. or i.p. with the same biweekly 3 dose regimen (vaccine+CpG). In three separate experiments with IT challenge doses of  Klebsiella  O1:K2 at 7.6, 9.5, and 7.6×10 4  CFU/mouse, respectively, we observed protection in i.n. vaccinated mice (p=0.047, Logrank test) and no protection in i.p. vaccinated mice ( FIG. 8 , top) when compared to control (PBS only) animals. There was a delayed time to death among i.n. immunized mice (median survival of 11 days) in comparison to i.p. immunized (median survival of 7 days) and control animals (median survival of 9.5 days) The severity of pneumonia by weight loss for i.n. immunized mice was less than i.p. vaccinated mice and control mice ( FIG. 8 , bottom). The peak percent weight loss was 14.0% (95% CI 10.1-17.9) in the IN group, 17.4% (95% CI 12.7-22.1) in the IP group, and 24.7% (95% CI 19.4-30.1) in the control group; significant differences were observed between the i.n. immunized and control group, but not between i.p. immunized and controls. 
     Given the survival benefit and reduced organ bacterial load among immunized mice, we hypothesized that the vaccine induced antibodies that enhanced the uptake and killing of bacteria by macrophages. In the macrophage killing assay, freshly isolated primary macrophages were allowed to phagocytose and kill bacteria that were pre-opsonized by heat inactivated serum or BALF samples from control and immunized mice. A single representative “high titer” immune BALF sample (ELISA IgG=200 ng/ml, IgA=1.8 ODU), “low titer” control BALF sample (ELISA IgG=1 ng/ml, IgA=0.7 ODU), and a “high titer” immune serum sample (ELISA IgG of 230 mg/ml, no IgA) was selected for the following in vitro assays. 
     The killing capacity of PM on  Klebsiella  O1:K2 was examined at 24 hours in three independent experiments with each containing two replicates at each time point. ( FIG. 9A ) Immune BALF mediated greater killing in comparison to control BALF or untreated bacteria. Immune serum also mediated greater killing in comparison to control BALF and untreated bacteria and was statistically superior to that of immune BALF. Control BALF mediated a moderate amount of killing in comparison to untreated bacteria; suggesting that additional non-immunoglobulin, non-complement opsonization may have a role. 
     Since the vaccine was designed to elicit antibodies against conserved epitopes in GNB, the ability of these antibodies to enhance the killing of another heterologous GNB,  Pseudomonas aeruginosa  (PA01), was tested in two separate experiments conducted in duplicate. Killing was assessed at 24 hours with PM infected with PAO1 that was pre-opsonized with the same serum and BALF samples as in the previous experiments. ( FIG. 9B ) Immune BALF and immune serum elicited significantly higher killing than either control BALF or untreated bacteria The opsonic activity of control BALF was not significantly different from no treatment. 
     Since AM may be more relevant to the pneumonia model, we measured the killing function of AM on PAO1, in two separate experiments conducted in duplicate. The highest killing activity was found with immune BALF followed by intermediate killing with immune serum treated bacteria; however neither treatment achieved statistical difference from control BALF treated bacteria ( FIG. 9C ). The control BALF was not different from untreated bacteria. 
     In order to further dissect out the potential role of anti-CGL antibody opsonization of bacteria on macrophage-mediated killing, two separate experiments with duplicates of each condition were conducted as in the previous experiments using immune serum that was diluted 1000-fold (with sterile PBS) in order to mimic the concentration of anti-CGL IgG in the immune BALF. In separate reaction tubes, L-NIL was added to macrophages infected with PAO1 pre-opsonized with immune serum in order to block nitric oxide production in macrophages. At 5 hours, immune serum and immune BALF demonstrated superior killing compared to control BALF and untreated bacteria. ( FIG. 10 ) The 1000-fold dilution of the immune serum abolished killing, suggesting a potential role for anti-CGL IgA as a mediator of killing. Killing was also abrogated when L-NIL was added to macrophages, suggesting that nitric oxide production is necessary for macrophage-mediated killing, independent of opsonin. On the whole, opsonization of these two heterologous GNB with a single representative sample of immune serum and BALF seems to mediate killing activity with PM, but this was not observed with this particular assay when using AM. 
     Example 10 
     Protection Against Respiratory Tularemia with dLPS-J5/OMP Vaccine with CpG ODN 
     BALB/c mice were immunized with the vaccine at 1 mcg/mouse intranasally at days 0, 14 and 28. One group of mice received the vaccine+CpG at 25 mcg/mouse (&amp;/group), another received vaccine alone (i.e. no CpG) (n=7), a third group received CpG alone (n=3) and a fourth group received saline (n=3). Twenty-eight days after the final immunization, all mice were administered 8-10,000 CFUs of the LVS strain of  F. tularensis  and followed for survival. 
     No difference was observed between the CpG alone and saline groups. Hence, they were grouped together as “control”. Similarly, since there was no difference between vaccine alone and vaccine+CpG, they were grouped together as “vaccinated”. Analysis of survival by the Kaplan Meier method ( FIG. 11 ) showed a difference in survival between control and vaccinated that was significant at a p value of 0.0012. Thus, the data presented herein suggests that immunization with the endotoxin vaccine may protect the subjects from lethal inhalation tularemia. Based on the results disclosed herein, the mechanism of action of the vaccine in protecting the immunized mice from developing the infection was examined. 
     Immunization of BALB/c mice i.n. with vaccine and CPG or CPG alone at time 0, day 14 and day 28 induced IgG and IgA antibodies against the J5 CGL in both serum and BAL fluid. Intratracheal challenge with LVS 4 weeks after the last immunization with vaccine+CPG revealed 22/36 mice survived compared to 1/18 mice immunized with CPG and 1/10 PBS controls (p&lt;0.0001) ( FIG. 12 ). Mice immunized with vaccine+CPG had fewer viable FT colonies in lung homogenates (p&lt;0.0087), and less extra-pulmonary dissemination to liver and spleen than CPG controls (p&lt;0.01) ( FIGS. 13A-13E ). Conceivably, the lower levels of cytokine (IL-12, TNFa, IFNg and IL-4) mRNA in lung and liver homogenates were due to fewer bacteria (Table 4). Immunized animals also had fewer neutrophils recruited to the lungs ( FIG. 13D ). Based on these data, BALB/c mice were immunized i.n. with either CPG alone or CPG+vaccine using the same immunization schedule. Four weeks later, mice were challenged i.t. with ˜10 cfu of SchuS4. Whereas 4/18 mice receiving CPG alone survived, 13 of 20 mice immunized with vaccine+CPG survived (p&lt;0.01). The present invention contemplates determining the ability of post-immunization BAL and sera to kill FT in vitro and identifying the epitope to which the anti-CGL antibody binds. However, based on the data presented herein it is concluded that i.n. immunization against FT with this vaccine and CPG merits further investigation. Additionally, the present invention contemplates assessing the efficacy of the vaccine disclosed herein in protection against plague. Furthermore, the vaccine efficacy will be evaluated in a second animal model as well (“two animal” rule). 
     
       
         
           
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 The levels of pro-inflammatory cytokines (g/mg 
               
               
                 protein) in control and vaccinated mice. 
               
            
           
           
               
               
               
               
               
               
            
               
                   
                 IFN-g 
                 IL-1a 
                 IL-6 
                 KC 
                 TNF-a 
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                   
                 C 
                 V 
                 C 
                 V 
                 C 
                 V 
                 C 
                 V 
                 C 
                 V 
               
               
                   
                   
               
            
           
           
               
               
               
               
               
               
               
               
               
               
               
            
               
                 Lung D0 
                 44 
                 53 
                 205 
                 174 
                 98 
                 60 
                 85 
                 80 
                 1289 
                 632 
               
               
                 Lung D3 
                 121 
                 60 
                 1023 
                 975 
                 598 
                 367 
                 861 
                 577 
                 2137 
                 1067 
               
               
                 Liver D0 
                 33 
                 39 
                 97 
                 115 
                 170 
                 205 
                 30 
                 28 
                 1041 
                 1206 
               
               
                 Liver D3 
                 186 
                 35 
                 1120 
                 257 
                 1011 
                 163 
                 589 
                 118 
                 6287 
                 1027 
               
               
                   
               
               
                 Cytokines analyzed from control (C) and vaccinated (V) mice. Samples pooled and analyzed by BioPlex on day of Ft challenge (D0) and 3 days later (D3). 
               
            
           
         
       
     
     The following references were cited herein:
     Bauer S.  Proc Natl Acad Sci USA  2001; 98:9247-9242.   Bhattacharjee A. K. et al.,  J Infect Dis  1996; 173:1157-1163.   Bhattacharjee A. K. et al.,  J Infect Dis  1994; 170:622-629.   Bhattacharjee A. K. et al.,  Infect Immun  2002; 70(7):3324-9.   Brandtzaeg P.,  Vaccine  2007; 25(30): 5467-84.   Chu R. S. et al.,  Infect Immun  2000; 68(3): 1450-1456.   Cooper C. L. et al.,  Vaccine  2004; 13:136-143.   Cross A. S. et al.,  Vaccine  2003; 21:4576-4588.   Cross A. S. et al.  J Infect Dis  2001; 183:1079-1086.   Cross A. S. et al.,  Vaccine  2004; 22:812-817.   Cross A. S. et al.,  Infect Immun  1993; 61(7):2741-7.   Deng et al.,  J Immunol  2004; 173(8):5148-55.   DiGiandomenico et al.,  Proc Natl Acad Sci USA  2007; 104(11): 4624-9.   Elkins et al.,  J Immunol  1999; 162(4): 2291-8.   Gao J. J. et al.,  Immunol  2001; 166:6855-6860.   Halperin S. et al.,  Vaccine  2003; 21:2461-2467.   Hemmi H. et al.  Nature  2000; 408:740-744.   Hirano et al.,  FEMS Immunol Med Microbiol  2003; 35(1): 1-10.   Jiao et al.,  Infect Immunol  2002; 70(11): 5982-9.   Joseph A. et al.,  Vaccine  2002; 20:3342-3354.   Kang et al.,  Infect Immunol  2005; 73(11): 7495-501.   Khan A. Q. et al.  J Immunol  2004; 172(1):532-539.   Klinman D. M.  Expert Rev Vaccines  2003; 2(2):305-315.   Klinman D. M.  Infect Immun  1999; 67(11):5658-63.   LaForce et al.,  J Infect Dis  1980; 142(3):421-31.   Lu et al.,  J Immunol  2006; 176(7): 3890-4.   Malanchere-Bres E. et al.,  J Virol  2001; 75(14):6482-6491.   McCluskie M. J. et al.,  Vaccine  2001; 19: 2657-2660.   McCluskie and Davis.,  Vaccine  1999; 18(3-4): 231-7.   Nichani et al.,  Vet Immunol Immunopathol  2007; 115(3-4):357-68.   Opal S. M. et al.,  Shock  2001; 15(4):285-290.   Opal S. M. et al.,  J Infect Dis  2005; 192(12):2074-80.   Orr et al.,  Infect Immun  1993; 61(6): 2390-5.   Renegar et al.,  J Immunol  2004; 173(3): 1978-86.   Robbins et al.,  Clin Infect Dis  1992; 15(2):346-361.   Rothenfusser S. et al.,  Curr Opin Mol Ther  2003; 5(2):98-106.   Snoeck et al.,  Vet Res  2006; 37(3):455-67.   Trautmann et al.,  Infect Immun  1994; 62(4): 1282-8.   Van d et al.,  Infect Immun  1996; 64(12): 5263-8.   Von Hunolstein C. et al.,  Int Immunol  2000; 12(3):295-303.   Weighardt H. et al,  J Immunol  2000; 165:4537-4543.   Wild J. S, and Sur S.  Allergy  2001; 56(5):365-376.   Wongratanacheewin et al.,  Infect Immun  2004; 72(8): 4494-502.